See Full Document Text
Official Journal EN
of the European Union L series
2025/2068 16.10.2025
COMMISSION IMPLEMENTING REGULATION(EU) 2025/2068
of 15 October 2025
renewing the approval of the active substance milbemectin in accordance with Regulation (EC)
No 1107/2009 of the European Parliament and of the Council, and amending Commission
Implementing Regulation (EU) No 540/2011
(Text with EEA relevance)
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21 October 2009
concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC
and 91/414/EEC(1), and in particular Article 20(1) thereof,
Whereas:
(1) Commission Directive 2005/58/EC(2) included milbemectin as an active substance in Annex I to Council
Directive 91/414/EEC(3).
(2) Active substances included in Annex I to Directive 91/414/EEC are deemed to have been approved under Regulation
(EC) No 1107/2009 and are listed in Part A of the Annex to Commission Implementing Regulation (EU)
No 540/2011(4).
(3) The approval of the active substance milbemectin, as set out in Part A of the Annex to Implementing Regulation (EU)
No 540/2011, expires on 31 May 2026.
(4) An application for the renewal of the approval of the active substance milbemectin was submitted to Germany, the
rapporteur Member State, and the Netherlands, the co-rapporteur Member State, in accordance with Article 1 of
Commission Implementing Regulation (EU) No 844/2012(5)within the time period provided for in that Article.
(5) The applicant submitted the supplementary dossier required to the rapporteur Member State, the co-rapporteur
Member State, the Commission and the European Food Safety Authority (‘the Authority’) in accordance with
Article 6 of Implementing Regulation (EU) No 844/2012. The application was found to be admissible by the
rapporteur Member State.
(6) The rapporteur Member State prepared a draft renewal assessment report in consultation with the co-rapporteur
Member State and submitted it to the Authority and the Commission on 29 June 2017.
(7) The Authority made the supplementary summary dossier available to the public. The Authority also circulated the
draft renewal assessment report to the applicant and to the Member States for comments and launched a public
consultation on it. The Authority forwarded the comments received to the Commission.
(1) OJ L 309, 24.11.2009, p. 1, ELI: http://data.europa.eu/eli/reg/2009/1107/oj.
(2) Commission Directive 2005/58/EC of 21 September 2005 amending Council Directive 91/414/EEC to include bifenazate and
milbemectin as active substances (OJ L 246, 22.9.2005, p. 17, ELI: http://data.europa.eu/eli/dir/2005/58/oj).
(3) Council Directive 91/414/EEC of 15 July 1991 concerning the placing of plant protection products on the market (OJ L 230,
19.8.1991, p. 1, ELI: http://data.europa.eu/eli/dir/1991/414/oj).
(4) Commission Implementing Regulation (EU) No 540/2011 of 25 May 2011 implementing Regulation (EC) No 1107/2009 of the
European Parliament and of the Council as regards the list of approved active substances (OJ L 153, 11.6.2011, p. 1, ELI: http://data.
europa.eu/eli/reg_impl/2011/540/oj).
(5) Commission Implementing Regulation (EU) No 844/2012 of 18 September 2012 setting out the provisions necessary for the
implementation of the renewal procedure for active substances, as provided for in Regulation (EC) No 1107/2009 of the European
Parliament and of the Council concerning the placing of plant protection products on the market (OJ L 252, 19.9.2012, p. 26, ELI:
http://data.europa.eu/eli/reg_impl/2012/844/oj).
ELI: http://data.europa.eu/eli/reg_impl/2025/2068/oj 1/8EN
OJ L, 16.10.2025
(8) In June 2019, the Authority requested additional information from the applicant on the endocrine disrupting
properties of milbemectin pursuant to Article 13(3a), first subparagraph, of Implementing Regulation (EU)
No 844/2012. The applicant submitted information to the Authority to assess whether the scientific criteria for the
determination of endocrine disrupting properties set out in point 3.6.5 and point 3.8.2 of Annex II to Regulation
(EC) No 1107/2009 were met.
(9) In May 2023, the rapporteur Member State made an updated draft renewal assesment report available to the
Authority, the Member States and the Commission. In its updated draft renewal assessment report, the rapporteur
Member State considered the additional information regarding the criteria to identify endocrine disrupting
properties and concluded that milbemectin does not meet the endocrine disrupting criteria for humans nor for non-
target organisms.
(10) On 5 July 2023, the Authority communicated to the Commission its conclusion(6) indicating that, taking into
account the approval criteria set out in Annex II to Regulation (EC) No 1107/2009, plant protection products
containing milbemectin can be expected to meet the approval criteria provided for in Article 4 of Regulation (EC)
No 1107/2009.
(11) The Commission presented a renewal report to the Standing Committee on Plants, Animals, Food and Feed on
11 March 2025 and a draft of this Regulation on 9 July 2025.
(12) The Commission invited the applicant to submit its comments on the conclusion of the Authority and, in accordance
with Article 14(1), third subparagraph, of Implementing Regulation (EU) No 844/2012, on the renewal report. The
applicant submitted its comments, which have been carefully examined and taken into due consideration.
(13) It has been established with respect to one or more representative uses of at least one plant protection product
containing the active substance milbemectin that the approval criteria provided for in Article 4 of Regulation (EC)
No 1107/2009 are satisfied.
(14) It is therefore appropriate to renew the approval of milbemectin. In accordance with Article 14(1) of Regulation (EC)
No 1107/2009, read in conjunction with Article 6 thereof, and in the light of current scientific and technical
knowledge and the outcome of the risk assessment, it is, however, necessary to provide for certain conditions, in
particular, to reduce drift to terrestrial and aquatic areas outside the treated field, where appropriate.
(15) In addition, in order to increase the confidence in the conclusion that any possible aneugenicity and phototoxicity
potential of milbemectin does not pose a concern for human health, the applicant should provide information to
confirm the absence of aneugenic potential of milbemectin and an in vitro phototoxicity study with milbemectin as
confirmatory information.
(16) Furthermore, given that new scientific and technical knowledge on comparative metabolism has been developed
during the evaluation process which was not available at the time of the submission of the supplementary dossier
for milbemectin, notably a Scientific Opinion(7) on testing and interpretation of comparative in vitro metabolism
studies published by EFSA in 2021, the applicant should provide an in vitro comparative metabolism study with
milbemectin as confirmatory information.
(6) EFSA Journal2023;21 (7):8126 Available online: www.efsa.europa.eu.
(7) EFSA PPR Panel (EFSA Panel on Plant Protection Products and their Residues), Hernandez-Jerez AF, Adriaanse P, Aldrich A, Berny P,
Coja T, Duquesne S, Focks A, Marinovich M, Millet M, Pelkonen O, Pieper S, Tiktak A, Topping CJ, Widenfalk A, Wilks M, Wolterink
G, Gundert-Remy U, Louisse J, Rudaz S, Testai E, Lostia A, Dorne J-L and Parra Morte JM, 2021. Scientific Opinion of the Scientific
Panel on Plant Protection Products and their Residues (PPR Panel) on testing and interpretation of comparative in vitro metabolism
studies. EFSA Journal2021;19(12):6970, 61 pp. https://efsa.onlinelibrary.wiley.com/doi/full/10.2903/j.efsa.2021.6970.
2/8 ELI: http://data.europa.eu/eli/reg_impl/2025/2068/ojEN
OJ L, 16.10.2025
(17) Finally, to increase the confidence in the conclusion that risk mitigation measures will be protective for all aquatic
organisms outside of the field and given that the scientific and technical knowledge on conducting the aquatic risk
assessment has evolved since the time the supplementary dossier for milbemectin were submitted, the applicant
should provide an updated risk assessment for the aquatic sediment organisms as confirmatory information.
(18) It is therefore appropriate to renew the approval of milbemectin subject to the conditions set out in the Annex to this
Regulation. Implementing Regulation (EU) No 540/2011 should be amended accordingly.
(19) Commission Implementing Regulation (EU) 2025/99(8) extended the approval period of milbemectin to 31 May
2026 in order to allow the renewal process to be completed before the expiry of the approval period of that active
substance. However, given that a decision on renewal has been taken ahead of that extended expiry date, this
Regulation should apply earlier than that date.
(20) The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on
Plants, Animals, Food and Feed,
HAS ADOPTED THIS REGULATION:
Article 1
Renewal of the approval of the active substance
The approval of the active substance milbemectin, as specified in Annex I to this Regulation, is renewed, subject to the
conditions laid down in that Annex.
Article 2
Amendments to Implementing Regulation (EU) No 540/2011
The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with Annex II to this Regulation.
(8) Commission Implementing Regulation (EU) 2025/99 of 21 January 2025 amending Implementing Regulation (EU) No 540/2011 as
regards the extension of the approval periods of the active substances Aureobasidium pullulans (strains DSM 14940 and DSM
14941), Bacillus amyloliquefaciens subsp. plantarum D747, benalaxyl-M, cyprodinil, dichlorprop-P, formetanate, fosetyl,
halosulfuron-methyl, imazamox, milbemectin, phenmedipham, pirimicarb, Pseudomonas sp. strain DSMZ 13134, pyrimethanil,
pyriofenone, pyroxsulam, spinosad, sulphur, Trichoderma harzianum Rifai strains T-22 and ITEM 908, Trichoderma asperellum
(formerly T. harzianum) strains ICC012, T-25 and TV-1, Trichoderma atroviride (formerly T. harzianum) strain T11, Trichoderma
gamsii (formerly T. viride) strain ICC080, triticonazole and ziram (OJ L, 2025/99, 22.1.2025, ELI: http://data.europa.eu/eli/reg_impl/
2025/99/oj).
ELI: http://data.europa.eu/eli/reg_impl/2025/2068/oj 3/8EN
OJ L, 16.10.2025
Article 3
Entry into force and date of application
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the
European Union.
It shall apply from 16 November 2025.
This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels, 15 October 2025.
For the Commission
The President
Ursula VON DER LEYEN
4/8 ELI: http://data.europa.eu/eli/reg_impl/2025/2068/ojANNEX I
Common Name,
Identification IUPAC Name Purity(1) Date of approval Expiration of approval Specific provisions
Numbers
Milbemectin M.A : (10E,14E,16E)- (1R,4S,5′S,6R,6′R,8R,13R, ≥ 950 g/kg 16 November 15 November 2040 For the implementation of the uniform
3
20R,21R,24S)- 21,24-dihydroxy- 2025 principles as referred to in Article 29(6) of
Milbemectin is a 5′,6′,11,13,22-pentamethyl-(3,7,19-trioxatetracy Regulation (EC) No 1107/2009, the conclusions
mixture of M.A clo[15.6.1.14,8.020,24] pentacosa-10,14,16, of the renewal report on milbemectin, and in
3
and M.A 22-tetraene)-6-spiro-2′- (tetrahydropyran)-2-one; particular Appendices I and II thereto, shall be
4
taken into account.
CAS No: M.A : (10E,14E,16E)- (1R,4S,5′S,6R,6′R,8R,13R,
4
M.A : 51596-10-2 20R,21R,24S)-6′-ethyl-21,24- dihydroxy- In this overall assessment Member States shall
3
M.A : 51596-11-3 5′,11,13,22-tetramethyl-(3,7,19-trioxatetracy pay particular attention to:
4
clo[15.6.1.14,8.020,24]
CIPAC No: 660 pentacosa-10,14,16,22-tetraene)-6- spiro- — the specification of the technical material as
2′-(tetrahydropyran)-2-one commercially manufactured;
— the protection of operators and workers
ensuring that conditions of use include the
application of adequate personal protective
equipment;
— the protection of bees and pollinators that
may be exposed to the active substance by
visiting the flowers present in the crop at the
time of application;
— the protection of aquatic organisms.
Conditions of use shall include risk mitigation
measures, in particular to reduce drift to
terrestrial and aquatic areas outside the
treated field, where appropriate.
ELI:
http://data.europa.eu/eli/reg_impl/2025/2068/oj
5/8
OJ
L,
16.10.2025
ENCommon Name,
Identification IUPAC Name Purity(1) Date of approval Expiration of approval Specific provisions
Numbers
The applicant shall submit confirmatory
information as follows:
1. to confirm that the bone marrow was exposed
in the available in vivo micronucleus test or to
confirm the absence of the aneugenic
potential of milbemectin;
2. an in vitro comparative metabolism study
with milbemectin (at least in the pivotal
species used to characterise milbemectin’s
toxicity and in comparison with human
metabolism);
3. an in vitro phototoxicity study with
milbemectin, testing the range of wavelengths
(between 290 and 700 nm) where the
absorption coefficient is > 10 L x mol-1x cm-1;
4. an updated risk assessment for the aquatic
sediment organisms in accordance with the
EFSA Guidance document on tiered risk
assessment for plant protection products for
aquatic organisms in edge of field surface
waters. To allow for proper comparison of the
sensitivity with other species, this
confirmatory information should include a
spiked-sediment test (OECD TG 218) and
spiked-water test (OECD TG 219) with
Chironomidae exposed to milbemectin,
where milbemycin A /milbemycin A is
3 4
present in the same ratio than in other
ecotoxicology studies.
The applicant shall submit to the Commission,
the Member States and the Authority the
information referred to the points above by
5 November 2027.
(1) Further details on the identity and specification of the active substance are provided in the renewal report.
6/8
ELI:
http://data.europa.eu/eli/reg_impl/2025/2068/oj
EN
OJ
L,
16.10.2025ANNEX II
The Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:
(1) in Part A, entry 110 on milbemectin is deleted;
(2) in Part B, the following entry is added:
Common Name,
Expiration of
No Identification IUPAC Name Purity(1) Date of approval Specific provisions
approval
Numbers
‘176 Milbemectin M.A : (10E,14E,16E)- (1R,4S,5′S,6R,6′ ≥ 950 g/kg 16 November 15 November For the implementation of the uniform principles as
3
R,8R,13R, 20R,21R,24S)- 2025 2040 referred to in Article 29(6) of Regulation (EC)
Milbemectin is a
21,24-dihydroxy-5′,6′,11,13,22 No 1107/2009, the conclusions of the renewal
mixture of M.A
3 -pentamethyl-(3,7,19-trioxatetracy report on milbemectin, and in particular Appendices
and M.A
4 clo[15.6.1.14,8.020,24] I and II thereto, shall be taken into account.
CAS No: pentacosa-10,14,16, 22-tetraene)-
In this overall assessment Member States shall pay
M.A : 51596-10-2 6-spiro-2′- (tetrahydropyran)-2-one;
3 particular attention to:
M.A : 51596-11-3
4 M.A : (10E,14E,16E)- (1R,4S,5′S,6R,6′ — the specification of the technical material as
4
CIPAC No: 660 R,8R,13R, 20R,21R,24S)-6′- commercially manufactured;
ethyl-21,24- dihydroxy-
— the protection of operators and workers ensuring
5′,11,13,22-tetramethyl-(3,7,19-triox
that conditions of use include the application of
atetracyclo[15.6.1.14,8.020,24]
adequate personal protective equipment;
pentacosa-10,14,16,22-tetraene)-6-
spiro-2′-(tetrahydropyran)-2-one — the protection of bees and pollinators that may be
exposed to the active substance by visiting the
flowers present in the crop at the time of
application;
— the protection of aquatic organisms.
Conditions of use shall include risk mitigation
measures, in particular to reduce drift to
terrestrial and aquatic areas outside the treated
field, where appropriate.
ELI:
http://data.europa.eu/eli/reg_impl/2025/2068/oj
7/8
OJ
L,
16.10.2025
ENCommon Name,
Expiration of
No Identification IUPAC Name Purity(1) Date of approval Specific provisions
approval
Numbers
The applicant shall submit confirmatory
information as follows:
1. to confirm that the bone marrow was exposed in
the available in vivo micronucleus test or to
confirm the absence of the aneugenic potential of
milbemectin;
2. an in vitro comparative metabolism study with
milbemectin (at least in the pivotal species used
to characterise milbemectin’s toxicity and in
comparison with human metabolism);
3. an in vitro phototoxicity study with milbemectin,
testing the range of wavelengths (between 290
and 700 nm) where the absorption coefficient is
> 10 L x mol-1x cm-1;
4. an updated risk assessment for the aquatic
sediment organisms in accordance with the EFSA
Guidance document on tiered risk assessment for
plant protection products for aquatic organisms
in edge of field surface waters. To allow for proper
comparison of the sensitivity with other species,
this confirmatory information should include a
spiked-sediment test (OECD TG 218) and spiked-
water test (OECD TG 219) with Chironomidae
exposed to milbemectin, where milbemycin A / 3
milbemycin A is present in the same ratio than
4
in other ecotoxicology studies.
The applicant shall submit to the Commission, the
Member States and the Authority the information
referred to the points above by 5 November 2027.
(1) Further details on the identity and specification of the active substance are provided in the renewal report.’
8/8
ELI:
http://data.europa.eu/eli/reg_impl/2025/2068/oj
EN
OJ
L,
16.10.2025